No Compounded Retatrutide Says the FDA + Tons of GLP-1 News
Update: 2025-08-05
Description
This week Dave covers all the obesity medicine news that will empower you to have more informed conversations with your doctor. This week's topics include:
FDA Statement on Non Branded GLP-1 Meds
Lilly is Getting to Root Cause Obesity Medicine, Beyond Tirzepatide
A Landmark Study for Mounjaro
Preview of Upcoming Earnings Calls
FDA Statement on Non Branded GLP-1 Meds
Lilly is Getting to Root Cause Obesity Medicine, Beyond Tirzepatide
A Landmark Study for Mounjaro
Preview of Upcoming Earnings Calls
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
